 Big Pharma Bristol Myers Squibb won approval for plaque psoriasis therapy Sotyktu on September 9th - the drug may have 4bn peak sales potential. Ventyx has a drug with the same MoA entering a Phase 2 study. Phase 1 data suggests it could be superior to Sotyktu. 